Welcome to LookChem.com Sign In|Join Free
  • or
N-(2,4-dinitrophenyl)-3,6,9,12,15,18,21,24-octaoxaheptacos-26-yn-1-amine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1196732-55-4

Post Buying Request

1196732-55-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1196732-55-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1196732-55-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,6,7,3 and 2 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1196732-55:
(9*1)+(8*1)+(7*9)+(6*6)+(5*7)+(4*3)+(3*2)+(2*5)+(1*5)=184
184 % 10 = 4
So 1196732-55-4 is a valid CAS Registry Number.

1196732-55-4Downstream Products

1196732-55-4Relevant academic research and scientific papers

Preparation and Evaluation of Radiolabeled Antibody Recruiting Small Molecules That Target Prostate-Specific Membrane Antigen for Combined Radiotherapy and Immunotherapy

Genady, Afaf R.,Janzen, Nancy,Banevicius, Laura,El-Gamal, Mahmoud,El-Zaria, Mohamed E.,Valliant, John F.

, p. 2660 - 2673 (2016)

The feasibility of developing a single agent that can deliver radioactive iodine and also direct cellular immune function by engaging endogenous antibodies as an antibody-recruiting small molecule (ARM) was determined. A library of new prostate-specific membrane antigen (PSMA)-binding ligands that contained antibody-recruiting 2,4-dinitrophenyl (DNP) groups and iodine were synthesized and screened in vitro and in vivo. A lead compound (9b) showed high affinity for PSMA and the ability to bind anti-DNP antibodies. Biodistribution studies of the iodine-125 analogue showed 3% ID/g in LNCaP xenograft tumors at 1 h postinjection with tumor-to-blood and tumor-to-muscle ratios of 10:1 and 44:1, respectively. The radiolabeled analogue was bound and internalized by LNCaP cells, with both functions blocked using a known PSMA inhibitor. A second candidate showed high tumor uptake (>10% ID/g) but had minimal binding to anti-DNP antibodies. The compounds reported represent the first examples of small molecules developed specifically for combination immunotherapy and radiotherapy for prostate cancer.

CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS

-

, (2011/09/14)

The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an ant

Chemical control over immune recognition: A class of antibody-recruiting small molecules that target prostate cancer

Murelli, Ryan P.,Zhang, Andrew X.,Michel, Julien,Jorgensen, William L.,Spiegel, David A.

supporting information; experimental part, p. 17090 - 17092 (2010/03/25)

(Figure Presented) Prostate cancer is the second leading cause of cancer-related death among the American male population, and society is in dire need of new approaches to treat this disease. Here we report the design, synthesis, and biological evaluation

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1196732-55-4